IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3

IRIDEX CORP

Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026

$0.77−0.04 (-5.48%)

Close on Oct 19, 2026

Market cap: $13.41M
P/E (TTM): –
Dividend yield: –

Dividends

Iridex has not reported a dividend

No dividend per share appears in Iridex's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Iridex's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IRIX.

Revenue growth3.7% · median 7.5%

Gross margin35.9% · median 49.6%

Operating margin-5.4% · median -23.5%

Net margin-6.9% · median -2.1%

Company	Revenue	Growth
SGHT	$83.38M	+9.3%
LNSR	$60.26M	+3.3%
IRIX	$51.57M	+3.7%
CV	$13.89M	+11.0%
ESMC	$12.74M	+5.7%
FOCL	–	–

Company

Next earnings (est.): Nov 11, 2026, after close
Exchange: Nasdaq
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: January 3
Employees: 93
Held by institutions: 12.4%
Auditor: BPM LLP
SEC CIK: 1006045

Advertisement
300 × 250